Document:

exv10w1

 

COUNTRYWIDE BANK, N.A.

NON-EMPLOYEE DIRECTORS’ FEE PLAN

(Adopted October 27, 2005)

SECTION 1

PURPOSE

     The Countrywide Bank, N.A. Non-Employee Directors’ Fee Plan (the “Plan”) has been established
by Countrywide Bank, N.A. (the “Bank”), effective as of October 27, 2005 (the “Effective Date”) to
attract and retain as members of its Board of Directors persons who are not employees of the Bank
or any of its subsidiaries or affiliates but whose business experience and judgment are a valuable
asset to the Bank and its subsidiaries. The Plan provides for the payment to Directors of fees in
the form of some or all of the following: Annual Retainer Fee, Chairman Retainer Fee, Meeting
Fees, and Restricted Stock Awards (generally, the “Director Fees”).

SECTION 2

DIRECTORS COVERED

     As used in the Plan, the term “Director” means any person who is elected to the Board of
Directors of the Bank as of the Effective Date or at any time thereafter, and is not an employee of
the Bank or any of its subsidiaries or affiliates.

SECTION 3

FEES PAYABLE TO DIRECTORS

     3.1     Annual Retainer Fee. Each Director shall be entitled to an annual retainer fee
(the “Retainer Fee”) to be paid quarterly on the first business day of the quarter for which the
Director serves in the capacity as a Director (excluding, on a pro rata basis, the month in which
he or she is first elected a Director and any whole months in which he or she did not serve in such
capacity). The amount of the Annual Retainer Fee shall be as determined in the discretion of the
Board of Directors of the Bank (the “Board”) and the Compensation Committee of the Board of
Directors of Countrywide Financial Corporation (the “Parent Compensation Committee”), with such
amount initially set at Fifty Thousand ($50,000.00) per year until such time as the Board and
Parent Compensation Committee adjust such amount. In the event the Parent Compensation Committee
is not in existence at any time while this Plan is in effect, then the term “Parent Compensation
Committee” shall refer to such other committee of the Board of Directors of Countrywide Financial
Corporation as its Board of Directors shall designate as having the powers of the Compensation
Committee, or if no such committee is in existence, to the Board of Directors of Countrywide
Financial Corporation.

     3.2     Chairman Retainer Fee. A Director who serves as Chairman of the Board or any
committee created by the Board shall be entitled to an additional annual retainer fee (the
“Chairman Retainer Fee”) to be paid quarterly on the first business day of the quarter for which
the Director serves in the capacity as a chairman (excluding, on a pro rata basis, the month in
which he or she is first selected to be the chairman and any whole months in which he or she did
not serve in such capacity). The amount of the Chairman Retainer Fee shall be as determined in

1

 

the discretion of the Board and Parent Compensation Committee, with such amount initially set
at Five Thousand ($5,000.00) per year until such time as the Board and Parent Compensation
Committee adjust such amount.

     3.3     Meeting Fees. A Director who attends a meeting of the full Board shall be
entitled to an additional fee (the “Meeting Fee”) to be paid on the first business day following
the day on which the meeting was held. The amount of the Meeting Fee shall be as determined in the
discretion of the Board and Parent Compensation Committee, with such amount initially set at One
Thousand Five Hundred Dollars ($1,500.00) for each Board meeting attended in person and One
Thousand Dollars ($1,000.00) for each Board meeting attended other than in person, in a manner
acceptable to the Board, until such time as the Board and Parent Compensation Committee adjust such
amounts.

SECTION 4

RESTRICTED STOCK.

     4.1     Annual Restricted Stock Award. Annually, on the first business day of April, each
Director shall be granted shares of Countrywide Financial Corporation common stock, par value $0.05
per share (the “Stock”), subject to certain restrictions set forth below (the “Restricted Stock”).
The number of shares covered by the Restricted Stock Award shall be equal to that number of shares
whose aggregate value (based on the Fair Market Value of a share of Stock on the date of grant)
equals Fifty-Six Thousand Dollars ($56,000.00), until such time as the Board and Parent
Compensation Committee adjust such amounts, rounded down to the next whole share. The term “Fair
Market Value” shall be as defined in the 2000 Equity Incentive Plan of Countrywide Financial
Corporation or any successor plan (as defined in Section 6.6 below).

     4.2     Issuance of Certificates. As soon as practicable following the date of grant of a
Restricted Stock Award, Countrywide Financial Corporation (the “Company”) shall issue certificates
(the “Certificates”) to the Director receiving the Restricted Stock Award, representing the number
of shares of Stock covered by the Award. Each Certificate shall bear a legend describing the
restrictions on such shares imposed by this Section 4 and may be retained by the Company or its
designee during the Restricted Period.

     4.3     Rights. Upon issuance of the Certificates, the Directors in whose names they are
registered shall, subject to the restrictions of this Section 4, have all of the rights of a
shareholder with respect to the shares represented by the Certificate, including the right to vote
such shares and to receive cash dividends and other distributions thereon.

     4.4     Restricted Period. The shares covered by Awards granted under this Section 4 may
not be sold or otherwise disposed of within six (6) months following their grant date (unless such
sale would not affect the exemption under Rule 16b-3 of the Securities and Exchange Commission) and
in addition shall be subject to the restrictions of this paragraph 4 during the “Restricted
Period.” The Restricted Period shall be the period commencing as of the date of grant and shall
lapse with respect to all of the Restricted Stock as of the business day immediately preceding the
anniversary date of the grant. Notwithstanding the foregoing, the Restricted Period shall lapse
and the Director shall become fully vested in the Restricted Stock upon the earliest of the
following to occur:

2

 

	 	(i)	 	The date of the Director’s death or disability (as defined by the Company’s
Board);
	 
	 	(ii)	 	The date of a Corporate Change (as defined in Section 9 of the 2000 Plan); or
	 
	 	(iii)	 	The date on which the Director becomes a Director Emeritus.

     4.5     Restrictions. All shares covered by Awards granted under this Section 4 shall be
subject to the following restrictions during the Restricted Period:

	 	(i)	 	Except as may otherwise be provided by the Company’s Board, the shares may not
be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of.
	 
	 	(ii)	 	Any additional common shares of the Company or other securities or property
issued with respect to shares covered by Awards granted under this Section 4 as a
result of any stock dividend, stock split or reorganization, shall be subject to the
restrictions and other provisions of this Section 4.
	 
	 	(iii)	 	A Director shall not be entitled to receive any shares prior to completion of
all actions deemed appropriate by the Company to comply with federal or state
securities laws and stock exchange requirements.

     4.6     Forfeiture. Except as otherwise provided in Section 4.4(i), (ii) and (iii), in
the event that the Director’s Date of Termination occurs prior to the business day immediately
preceding the first anniversary of the date of grant, the Director shall forfeit any and all rights
and interests with respect to such unvested Restricted Stock and the Company shall have the right
to cancel any such Certificates evidencing such Restricted Stock.

     4.7     Date of Termination. A Director’s “Date of Termination” shall be the date on
which the Director is no longer providing services to the Bank as a Director.

SECTION 5

CHANGE IN CONTROL

     In the event of a Corporate Change, the Restricted Period with respect to all unvested
Restricted Stock shall immediately lapse and the Director shall become fully vested in such shares
of Restricted Stock.

SECTION 6

OPERATION AND ADMINISTRATION

     6.1     Administration.

	 	(i)	 	The Plan and all benefits pursuant thereto shall be administered by the full
Board.
	 
	 	(ii)	 	The Board shall have the authority and discretion to interpret and administer
the Plan, to establish, amend and rescind any rules and regulations relating to the
Plan

3

 

	 	 	 	and to determine the terms and provisions of any Award Agreement made pursuant to
the Plan. All questions of interpretation with respect to the Plan, the benefits
established herein, the number of shares of Stock, or other security, or rights
granted and the terms of any agreements evidencing any of the Director Fees (the
“Award Agreements”), including the timing, pricing, and amounts of Awards, shall be
determined by the Board, and its determination shall be final and conclusive upon
all parties in interest. In the event of any conflict between an Award Agreement
and this Plan, the terms of this Plan shall govern.
	 
	 	(iii)	 	Except to the extent prohibited by applicable law or the applicable rules of a
stock exchange, the Board may delegate to the officers or employees of the Bank the
authority to execute and deliver such instruments and documents, to do all such acts
and things, and to take all such other steps deemed necessary, advisable or convenient
for the effective administration of the Plan in accordance with its terms and purpose,
except that the Board may not delegate any discretionary authority with respect to
substantive decisions or functions regarding the Plan or benefits and Awards
thereunder, including, but not limited to, decisions regarding the timing, eligibility,
pricing, amount or other material terms of such benefits or Awards. Any such delegation
may be revoked by the Board at any time.
	 
	 	(iv)	 	To the extent that the Board determines that the restrictions imposed by the
Plan preclude the achievement of the material purposes of the benefit provided herein
in jurisdictions outside the United States, if applicable, the Board will have the
authority and discretion to modify those restrictions as the Board determines to be
necessary or appropriate to conform to applicable requirements or practices of
jurisdictions outside of the United States.

     6.2     Limits of Liability.

	 	(i)	 	Any liability of the Bank to any Director with respect to an Award shall be
based solely upon contractual obligations created by the Plan and the applicable Award
Agreement.
	 
	 	(ii)	 	Neither the Bank, nor any member of the Board, nor any other person
participating in any determination of any question under the Plan, or in the
interpretation, administration or application of the Plan, shall have any liability to
any party for any action taken or not taken in good faith under the Plan except as may
be expressly provided by statute.

     6.3     Rights of Directors. Nothing contained in this Plan or in any Award Agreement (or
in any other documents related to this Plan or to any Award or Award Agreement) shall confer upon
any Director any right to continue in the service of the Bank or any of its subsidiaries or
affiliates, constitute any contract or limit in any way the right of the Bank or any of its
subsidiaries or affiliates to change such person’s compensation or other benefits or to terminate
the service of such person with or without cause or confer any right on the part of such person to
be nominated for reelection to the Board, to be reelected to the Board or to be appointed to any
committee of the Board.

4

 

     6.4     Form and Time of Elections. Any election required or permitted under the Plan
shall be in writing, and shall be deemed to be filed when timely delivered to the Company. Any
election to defer Director Fees, as provided in Section 9, shall be irrevocable after the
commencement of the year for which it is filed, and such election shall remain in effect with
respect to any subsequent years unless a new election with respect to such subsequent years is
filed in accordance with rules established by the Board, in which case such new election shall be
applicable with respect to such subsequent years.

     6.5     Action by Bank. Any action required or permitted to be taken by the Bank shall be
by resolution of the Board, or by action of one or more members of the Board (including a committee
of the Board) who are duly authorized to act for the Board or (except to the extent prohibited by
the provisions of Rule 16b-3, applicable local law, the applicable rules of any stock exchange, or
any other applicable rules) by a duly authorized officer of the Bank.

     6.6     2000 Equity Incentive Plan. Any shares of Stock awarded to, or subject to Awards
granted to Directors under this Plan as Director Fees shall be issued pursuant to the 2000 Equity
Incentive Plan of Countrywide Financial Corporation (the “2000 Plan”) or any successor plan,
subject to all of the terms and conditions herein. Except in the event of conflict, all provisions
of the 2000 Plan shall apply to this Plan. In the event of any conflict between the provisions of
the 2000 Plan and this Plan, this Plan shall control, provided that the Director Fees granted
herein may not exceed the share limitations set forth in the 2000 Plan.

SECTION 7

MISCELLANEOUS

     7.1     Beneficiaries. Each Director or former Director entitled to payment of Director
Fees hereunder, from time to time may name any person or persons (who may be named contingently or
successively) to whom any Director Fees earned by him or her and payable to him or her are to be
paid in case of his or her death before he or she receives any or all of such Director Fees. Each
designation will revoke all prior designations by the same Director or former Director, shall be in
form prescribed by the Bank, and will be effective only when filed by the Director or former
Director in writing with the Secretary of the Bank during his lifetime. If a deceased Director or
former Director shall have failed to name a beneficiary in the manner provided above, or if the
beneficiary named by a deceased Director or former Director dies before him or before payment of
all the Director’s or former Director’s Director Fees, the Bank, in its discretion, may direct
payment in a single sum of any remaining Director Fees to either:

	 	(i)	 	any one or more or all of the next of kin (including the surviving spouse) of
the Director or former Director, and in such proportions as the Bank determines; or
	 
	 	(ii)	 	the legal representative or representatives of the estate of the last to die of
the Director or former Director and his last surviving beneficiary.

The person or persons to whom any deceased Director’s or former Director’s Director Fees are
payable under this paragraph will be referred to as his “beneficiary.”

     7.2     Alienation of Rights. Payment of Director Fees will be made only to the person
entitled thereto in accordance with the terms of the Plan, and Director Fees are not in any way
subject to the debts or other obligations of persons entitled thereto, and may not be voluntarily
or

5

 

involuntarily sold, transferred or assigned. When a person entitled to a payment under the
Plan, in the Bank’s opinion, is in any way incapacitated so as to be unable to manage his financial
affairs, the Bank may direct that payment be made to such person’s legal representative, or to a
relative or friend of such person for his benefit. Any payment made in accordance with the
preceding sentence shall be in complete discharge of the Bank’s obligation to make such payment
under the Plan.

     7.3     Unfunded Plan. The Plan shall be unfunded. Neither the Bank nor the Board shall
be required to segregate any assets that may at any time be represented by benefits or Awards made
pursuant to the Plan. Neither the Bank nor the Board shall be deemed to be a trustee of any
amounts to be paid under the Plan. Neither the Director nor any other person shall, by reason of
participation in the Plan, the deferral of a cash payment, acquire any right in or title to any
assets, funds or property of the Bank whatsoever prior to the date such shares of Stock or cash are
distributed. A Director shall have only a contractual right to the shares of Stock and cash, if
any, distributable under the Plan, unsecured by any assets of the Bank. Nothing contained in the
Plan shall constitute a guarantee by the Bank that the assets of the Bank shall be sufficient to
provide any benefits to any person. The Bank may, but shall not be obligated to, establish a trust
to hold assets for the purpose of satisfying obligations under this Plan.

     7.4     Adjustment Provisions. In the event of a corporate transaction involving the
Company or the Bank (including, without limitation, any stock dividend, stock split, extraordinary
cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off,
combination or exchange of shares), in addition to any adjustments made pursuant to Section 8 of
the 2000 Plan, the Board may make equitable adjustments to the Director Fees (including Deferred
Fees) to preserve the benefits or potential benefits of participation in the Plan.

     7.5     Gender and Number. Where the context admits, words in any gender shall include
any other gender, words in the singular shall include the plural and the plural shall include the
singular.

SECTION 8

AMENDMENT AND DISCONTINUANCE

     The Board may, at any time, amend or terminate the Plan, and may amend any Award Agreement,
provided that no amendment or termination may, in the absence of written consent to the change by
the affected Director (or, if the Director is not then living, the affected beneficiary), adversely
affect the rights of any Director or beneficiary under any Award granted under the Plan prior to
the date such amendment is adopted by the Board; and further provided, that adjustments pursuant to
paragraph 7.4 shall not be subject to the foregoing limitations of this Section 8. Notwithstanding
the foregoing, Sections 3.1, 3.2, 3.3 and 4.4 of the Plan cannot be amended or terminated without
the approval of the Parent Compensation Committee. Any amendment or discontinuance of the Plan
shall be prospective in operation only, and shall not affect the payment of any Director Fees
theretofore earned by any Director, or the conditions under which any such fees are to be paid or
forfeited under the Plan, unless the Director affected shall expressly consent thereto.

6

 

SECTION 9

ELECTIVE DEFERRALS

     9.1     DEFERRAL ELECTION

	 	(i)	 	General. A Director who is otherwise entitled to receive Director Fees
in the form of a cash payment under the terms of the Plan may elect to defer delivery
of all or a portion of such fees, subject to section 409A of the Internal Revenue Code
and the following terms of this Section 9 (once deferred, the “Deferred Fees”).
	 
	 	(ii)	 	Deferral Election. An election to defer the cash-based Director Fees
into a Cash Account and shall be filed prior to the first day of the calendar year in
which the cash would otherwise have been delivered to the Director. The election to
defer the Director Fees shall be made on an election form as provided by the Bank (the
“Deferral Election”).
	 
	 	 	 	The Deferral Election form shall provide for the amounts of the cash-based Director
Fees to be deferred and shall provide for the timing and method of distribution at
the end of the applicable deferral period.

     9.2     ACCOUNTS

	 	(i)	 	Cash Account. A Cash Account shall be maintained on behalf of each
Director who elects to defer the distribution of cash-based Director Fees provided
herein, for the period during which delivery of cash is deferred. At the beginning of
each calendar quarter, there shall be credited to the Director’s Cash Account
“interest” using a rate equal to the “Applicable Interest Rate” on the first day of the
calendar quarter. Such interest shall be determined on the balance in the Director’s
Cash Account as of the last day of each month for the preceding quarter. All amounts
otherwise due and payable to the Director shall be deemed received and credited to the
Director’s Cash Account as of the first day of the month in which the amount was due
and payable by the Bank to the Director. Unless otherwise agreed to by the Bank and the
Director, the “Applicable Interest Rate” shall be the annual percentage rate offered by
the Bank to its retail customers for a certificate of deposit having an “opening
deposit” amount equal to the balance in the Director’s Cash Account on the first day of
the applicable calendar quarter and having a term of 60 months, divided by 12. As of
the date of any distribution with respect to a Director’s Cash Account under Section
9.3, the balance credited to a Director’s Cash Account shall be reduced by the amount
of the distribution to the Director.
	 
	 	(ii)	 	Statement of Accounts. As soon as practicable after the end of each
Year, the Company shall provide each Director having a Cash Account under the Plan with
a statement of the transactions in such Accounts during that year and the Account
balances as of the end of the year.

     9.3     DISTRIBUTIONS

	 	(i)	 	General. Subject to the terms of this Section 9.3, a Director shall
specify, as part of his Deferral Election with respect to Deferred Fees, the time and
manner of the

7

 

	 	 	 	distribution of the amounts deferred pursuant to such election. In the event that no
election is made with respect to the timing or method of distribution as of the date
of the Director’s termination, the Director’s entire Cash Account shall be
distributed in a single lump sum as of the first anniversary the Director’s date of
termination.
	 
	 	(ii)	 	At the time of distribution of the Cash Account in accordance with the Director’s
Deferral Election, the Director shall receive a cash payment equal to the amount in his Cash
Account then subject to distribution.
	 
	 	(iii)	 	Termination of Deferral by Bank. The Board shall retain the right to
terminate, at any time, for any reason, or no reason, the deferral provisions under this
Section 9 (which may, but need not, be in conjunction with a termination of the Plan

     IN WITNESS WHEREOF, the Bank has caused this Director Fee Plan to be executed by its
duly authorized officer this 27th day of October, 2005

	 	 	 	 	 
	 	Countrywide Bank, N.A.

 	 
	 	By:  	/s/ James S. Furash
 	 
	 	 	James S. Furash 	 
	 	 	President and Chief Executive Officer 	 
	 

8exv10w1

 

EXHIBIT 10.1

AGREEMENT

This
Agreement, entered into on this 28th day of October, 2005, is made

Between

Cell Therapeutics, Inc., a company incorporated under the Laws of the State of Washington,
with registered offices at 501 Elliot Avenue West 400, Seattle, Washington
98119, U.S.A., represented by Mr. James A. Bianco, in his capacity as president and CEO
(hereinafter, “CTI”)

 - on one side -

and

Pharmaceutical Research Associates, Inc., a company incorporated under the Laws of
the State of Virginia, with its registered offices at 12120 Sunset Hills Road,
Suite 600, Reston, Virginia, 20190, U.S.A., represented by Patrick K. Donnelly, in his
capacity as President and CEO (hereinafter, ‘‘PRA”)

- on the other side -

(hereinafter, collectively, the “Parties”)

WHEREAS

	a)	 	CTI is an American listed biotech company, which operates in the field of research
and development of drugs for the curing of tumours;
	 
	b)	 	PRA is an American listed company specialized in the performance of services of
planning, organization and management of clinical trials;
	 
	c)	 	On or about September 24, 2002, the Parties entered into an agreement for the supply
of clinical trials development services in relation to the therapeutic protocol
No. AZA-III-02, named “An open label, randomized, phase III comparative trial of
BBR2778 + Rituximab versus Rituximab in the treatment of patients
with relapsed or refractory indolent Non- Hodgkin’s Lymphoma” (hereinafter, the
“Clinical Trial Agreement”);
	 
	d)	 	The Parties have been involved in a dispute arising out of the Clinical Trial Agreement;
	 
	e)	 	In particular, the Parties were involved in an ICC Arbitration Proceedings under the
Rules of the ICC International Court of Arbitration pursuant to the
arbitration clause contained in Art. 22 of the Clinical Trial Agreement, with venue in Zurich,
Switzerland (hereinafter, the ICC arbitration proceedings, the “Arbitration Proceedings”, and
the International Chamber of Commerce of Paris, the “ICC”);
	 
	f)	 	The Arbitration Proceedings was concluded with the issue of an award rendered on
September 27, 2005 (hereinafter, the “Award”), communicated to both of the Parties with an ICC
letter dated October 3, 2005, received by CTI and by PRA on
October 5, 2005;
	 
	g)	 	In accordance with the provisions of the “Operative Part of the final Award”, under
pages 161 — 162 of the same, having set-off between the Parties the amounts reciprocally owed by the
same, PRA owes CTI the balance amount indicated therein, plus interest at different

 

 

	 	 	rates and from different dates in relation to the various items of condemnation,
whose title is compensation for damages;
	 
	h)	 	To the best knowledge of the Parties, each of them has a right to appeal against the Award
and, in any event, the same may not cover all possible reciprocal causes of action arising
out of the clinical trial referred to above;
	 
	i)	 	PRA has offered CTI the spontaneous payment of the said balance amount, and to
irrevocably waive its right to appeal against the Award for any reason whatsoever and based
on any grounds;
	 
	j)	 	CTI intends to accept such a payment, and is available to irrevocably waive its right to
appeal against the Award for any reason whatsoever and based on any grounds;
	 
	k)	 	In addition, the Parties intend to resolve hereby all possible claims between them in
relation to the Clinical Trial Agreement and, in any event, the clinical trial governed by
the same in order to finally settle their business relationships in this regard, by way of
definitively renouncing to any reciprocal claims as hereunder set forth.

NOW THEREFORE, also in consideration of the recitals above which form an integral and substantial
part of this agreement (hereinafter, the “Contract”), the Parties agree as follows:

1.     Payment.

Upon execution of this Contract by the Parties PRA shall pay CTI the overall amount of Euro
560,683.39 pursuant to the Award. The above amount is inclusive of the interest
reciprocally due by the Parties as of October 19, 2005, pursuant to the Award
(hereinafter, the “Amount”).

The Amount shall be paid by PRA in immediately available funds as of today’s date by irrevocable
international wire transfer on the bank account of Cell Therapeutics Europe s.r.l., No. 30034914,
held at Unicredit Banca d’Impresa, Filiale di Cinisello Balsamo, Milan, Italy, IBAN IT 77 H 03226 32930 30034914, Swift Code BIC UNCRIT2VCNS.

2.     Reciprocal Waiver of the Right to Appeal against the Award.

The Parties reciprocally and irrevocably waive their right to promote any appeal against the
Award pursuant to applicable law.

More precisely, in consideration for PRA’s renouncing to appeal against the Award, CTI waives
its right to appeal against the Award.

3.     Reciprocal Releases and Waivers.

PRA irrevocably waives any claims, counter-claims, actions and demand under any causes of action,
known or unknown, in any jurisdictions towards CTI and any past, current or future
companies of the CTI Group, including its parent entities, subsidiaries, affiliates,
past and current officers, directors, employees, owners, successors, attorneys, representatives,
assigns, and heirs, in relation to the Clinical Trial Agreement and the Award, and, in any event,
any past and current relationships relating to the Clinical Trial referred to above.

2

 

In consideration for PRA’s waiver above, CTI irrevocably waives any claims,
counter-claims, actions and demand under any causes of action, known or unknown,
in any jurisdictions towards PRA and any past, current or future companies of the PRA
Group, including its parent entities, subsidiaries, affiliates, past and current officers,
directors, employees, owners, successors, attorneys, representatives, assigns, and heirs, in
relation to the Clinical Trial Agreement and the Award, and, in any event, any past and current
relationships relating to the Clinical Trial referred to above.

4.     Confidentiality.

The Parties hereto agree that this Contract, its contents and all matters relating to the
terms, negotiations and implementation of the Contract are confidential and are not to be disclosed
to any third parties; provided, however, that any Party may disclose information that is deemed
confidential hereunder in the event and to the extent that such disclosure (i) has already been
made public prior to the execution of this Contract in accordance with any of the following items,
(ii) is made in an action seeking to enforce the terms of the Contract or obligations arising
therefrom, (iii) is consented to in writing by the other Party hereto, (iv) is made to a Party’s
attorney, agent, accountant or lender, provided that such person has agreed to keep such
information confidential, or (v) is made according to disclosure under any court order or other
lawful process or regulatory procedure, including any regulations applicable to publicly listed
companies (including but not limited to the attaching of copy hereof as exhibit to a
“Form 8-K” filed with the U.S. Securities and Exchange Commission or similar type of filings).

5.     Entire Contract.

This Contract constitutes the entire agreement between the Parties and fully supersedes any and all
prior or contemporaneous oral and written understandings and agreements relative to the subject
matter hereof. No part of this Contract may be modified or integrated, except if
in writing and executed by a duly authorized representative of each of the Parties. This
Contract shall be executed in two original counterparts, duly signed and initialled on
each page by both of the Parties.

6.     Governing Law.

This Contract shall be construed in accordance with and it is governed by the Laws of the State of
Washington.

7.     Successors

This Contract shall be binding upon, and inure to the benefit of, the parties hereto
and their respective representatives, successors and assigns.

8.     Exclusive Jurisdiction.

All litigation relating to or arising under or in connection with this Contract shall be
brought only in the federal or state courts located in the State of Delaware, which shall have exclusive jurisdiction
to resolve any disputes with respect to this Contract, with each party irrevocably consenting to the
jurisdiction thereof for any actions, suits or proceedings arising out of or relating to this Contract.
The Parties irrevocably waive trial by jury in any legal action or proceeding relating to this
Contract or any other agreement entered into in connection herewith and for any counterclaim with respect
hereto. In the event of any breach of the provisions of this Contract, the non-breaching Party shall
be entitled to equitable relief, including in the form of injunctions and orders for specific

3

 

performance, where the applicable legal standards for such relief in such courts are met,
in addition to all other remedies available to the non-breaching Party with respect hereto
at law or in equity. In addition, the prevailing Party shall be entitled to its reasonable
attorneys’ fees, costs and expenses incurred in connection with any legal action or proceeding.

IN WITNESS
WHEREOF, the undersigned Parties have caused this instrument to be duly
executed as of the date and year first written above.

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]